40982-58-9

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Bis[(triMethylsilyl)oxy]pyridine is used as an intermediate in the synthesis of 3-Deazapyrimidine, which is a key component in the development of neoplasm inhibitors. These inhibitors are essential in the treatment of various types of cancer, as they target and inhibit the growth of tumor cells.
In the synthesis of 3-Deazapyrimidine, 2,4-Bis[(triMethylsilyl)oxy]pyridine serves as a crucial building block, providing the necessary structural framework for the formation of the final product. 2,4-Bis[(triMethylsilyl)oxy]pyridine's unique properties, such as its reactivity and stability, make it an ideal candidate for use in the development of novel cancer-fighting drugs.
Furthermore, the versatility of 2,4-Bis[(triMethylsilyl)oxy]pyridine allows it to be employed in the synthesis of other bioactive molecules with potential applications in the pharmaceutical industry. Its ability to form various derivatives and analogs enables researchers to explore a wide range of chemical modifications, potentially leading to the discovery of new and more effective therapeutic agents.

Upstream product

• 626-03-9 3-deazauracil 
• 999-97-3 1,1,1,3,3,3-hexamethyl-disilazane 
• 75-77-4 chloro-trimethyl-silane 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 3,3-difluoropyridine-2,4(1H,3H)- dione and 3-deaza-3-fluorouracil base and nucleoside derivatives

New 3-deaza-3-halouracil nucleosides including 3-deaza-3-fluorouridine and its 2′-deoxy and arabino analogues have been prepared by fluorination of protected precursors. The resulting 3,3-difluoropyridine-2,4(1H,3H)-dione derivatives underwent palladium-c

Synthesis of 5-fluorouracil derivatives containing an inhibitor of 5- fluorouracil degradation

The reactivities of 5-fluorouracil (5-FUra) degradation inhibitors, 2,4- (2) and 2,6-dihydroxypyridines (3), were investigated. Acylation of 2 and 2,4-bis(trimethylsilyloxy)pyridines with equimolar amounts of acid chlorides preferentially occurred at the 4-OH and 2-OH positions, respectively, and the structure of monobenzoylated 5-chloro-2,4-dihydroxypyridine (2b) was determined as 4-benzoyloxy-5-chloro-2-pyridone (5b) by X-ray crystallographic analysis. Compounds 2 and 3, as well as the N-2-tetrahydrofuryl (11), N- alkyl (12), and N-carbamoyl (14) derivatives of 2, exhibit dynamic keto-enol tautomerism. The acyl derivatives of these pyridines are labile and are thought to be active esters. Monoacyl ester derivatives of these pyridines were combined with 5-FUra analogs to develop novel antitumor agents containing an inhibitor of 5-FUra degradation. One of them, 3-[3-(6- benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl]-1-ethoxymethyl-5- fluorouracil (BOF-A2) (22b), was the most effective and is currently undergoing late phase-II clinical trials.